Rivaroxaban for cancer-associated venous thromboembolism

All cancers can increase the risk of developing venous thromboembolism (VTE), and anticoagulants should be considered as an optimal treatment for patients suffering from cancer-associated VTE. However, there is still a debate about whether the new oral anticoagulant, rivaroxaban, can bring better ef...

Descripción completa

Detalles Bibliográficos
Autores principales: Liang, Bo, Liang, Yi, Zhao, Li-Zhi, Zhao, Yu-Xiu, Gu, Ning
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10454885/
https://www.ncbi.nlm.nih.gov/pubmed/33913387
http://dx.doi.org/10.1177/00368504211012160

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10454885/
https://www.ncbi.nlm.nih.gov/pubmed/33913387
http://dx.doi.org/10.1177/00368504211012160

Ejemplares similares